Novo Nordisk Earnings: Raising Fair Value on Improving GLP-1 …

1 day ago · Novo Nordisk grew its top line and operating profit by 25% in 2024, as insulin rebate adjustments drove performance ahead of consensus. Sales of GLP-1 products were in-line …

CouponFollow Extension

25%
OFF

Novo Nordisk Earnings: Raising Fair Value On Improving GLP-1 …

3 weeks from now

1 day ago · Novo Nordisk grew its top line and operating profit by 25% in 2024, as insulin rebate adjustments drove performance ahead of consensus. Sales of GLP-1 products were in-line …

morningstar.com

42%
OFF

Novo Nordisk Earnings: Surge In Obesity Treatments

3 weeks from now

1 hour ago · We now think the GLP-1 market could grow 42% in 2025, from 54 billion USD to 77 billion USD, with Novo Nordisk seeing 30% GLP-1 growth. We still see a more than 200 billion …

morningstar.co.uk

52%
OFF

Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript - Nasdaq

3 weeks from now

18 hours ago · The sales increase was mainly driven by the continued uptake of Ozempic and the GLP-1 class growth. Novo Nordisk remains the market leader in the U.S. with more than 52% …

nasdaq.com

$3.28
OFF

NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up

3 weeks from now

1 day ago · For the full year, Novo Nordisk reported earnings of $3.28 per ADR, surpassing the Zacks Consensus Estimate of $3.16. NVO’s 2025 Outlook Novo Nordisk expects its sales to …

zacks.com

$140
OFF

Novo Nordisk Earnings: Raising Our FVE On GLP-1 Demand, But …

3 weeks from now

Aug 11, 2023 · We’re raising our fair value estimate for Novo Nordisk NOVO B to $140/DKK 950 from $130/DKK 900 following a strong second quarter and another full-year guidance increase …

morningstar.com

$140
OFF

Novo Nordisk Earnings: Raising Our FVE On GLP-1 Demand

3 weeks from now

Aug 10, 2023 · We're raising our fair value estimate for Novo Nordisk to $140/DKK 950 from $130/DKK 900 following a strong second quarter and another full-year guidance increase from …

morningstar.com

8%
OFF

Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales

3 weeks from now

May 2, 2024 · Administrative costs increased 8% in DKK and 9% at CER to DKK 1.2 billion. 2024 Outlook Updated. Novo Nordisk now expects its sales to grow in the band of 19-27% …

nasdaq.com

$50
OFF

Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading …

3 weeks from now

Jan 24, 2025 · Novo and Lilly are fighting for share in the global GLP-1 market, which surpassed $50 billion in 2024 and is likely to reach $200 billion by 2031 as supply and insurance …

morningstar.com

24%
OFF

Novo Nordisk: GLP-1 Leadership Redefining Chronic Care—Will …

3 weeks from now

Novo Nordisk delivered strong Q3 2024 results, with year-to-date sales and operating profit growth of 24% and 22%, respectively, driven by the continued success of GLP-1 drugs …

equisights.com

FAQs about Novo Nordisk Earnings: Raising Fair Value on Improving GLP-1 … Coupon?

How did Novo Nordisk A/S NVO perform in Q4 2024?

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 83 cents. The company had reported earnings of 71 cents per ADR in the year-ago quarter. See the ZacksEarnings Calendar to stay ahead of market-making news. ...

Which company has the largest GLP-1 market share?

Novo Nordisk: Despite the miss in Wegovy sales, Denmark-based Novo remains the market leader with its share of the GLP-1 market. CEO Lars Jørgensen said the company has 69% of the market share globally, and diabetes drug Ozempic specifically leads with a 46% share. The company also got approval for Wegovy for patients at risk of heart disease. ...

Are all GLP-1 providers created equal?

Recent earnings from Eli Lilly and Company ( LLY) and Novo Nordisk ( NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created equal. Yahoo Finance senior healthcare reporter Anjalee Khemlani discusses both companies' earnings results, with Eli Lilly seeing strong sales of its GLP-1 drugs Mounjaro and Zepbound. ...

Why is NVO stock gaining during pre-market hours?

The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product sales increased year over year, as well as greater insulin and Rare disease sales. NVO stock price is gaining during the pre-market hours today as investors are impressed by better-than-expected fourth-quarter results. ...

Are GLP-1 sales driving growth in diabetes & obesity care?

Overall, GLP-1 sales across diabetes and obesity care are driving growth as insulin and rare disease units decline, and 73% of third-quarter sales (and likely an even higher share of profits) are derived from GLP-1 therapies, largely semaglutide. ...

Is Novo Nordisk A branded diabetes treatment company?

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. ...